Evommune gives up on dermatitis drug after another ph. 2 fail
News from Fierce Biotech: Evommune gives up on dermatitis drug after another ph. 2 fail
Evommune
Evommune is a US clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. The company's pipeline is led by EVO101, an IRAK4 inhibitor in Phase 2 for chronic spontaneous urticaria and other inflammatory skin conditions, alongside additional earlier-stage programs. Evommune raised a $115M Series C to advance the pipeline.
Company Info
Sector:Biotechnology / Inflammation
Headquarters:Palo Alto, California, USA
Founded:2020
Website:www.evommune.com/
Upcoming Milestones & Key Dates
H2 2026
Clinical Trial
Continued Phase 2 readouts for EVO101 in chronic spontaneous urticaria
Q3 2026
Earnings
Q2 2026 earnings and pipeline update
Clinical Development Pipeline
EVO101
Target: IRAK4 inhibitor (degrader)EVO101
Target: IRAK4 inhibitor (degrader)EVO301
Target: To be confirmedRecent News
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes
Evommune is discontinuing development of its lead chronic spontaneous urticaria candidate after a mid-stage trial failed to meet efficacy benchmarks.
Evommune's lead drug fails in chronic hives, stock sinks
Endpoints News reports that Evommune's lead clinical candidate failed to meet primary endpoints in chronic hives, sending shares down on the readout.
Leadership Team
Luis Peña
Chief Executive Officer